

## Grifols Egypt donation centers receive first international plasma industry quality certification outside North America and Europe

- *First Grifols Egypt donation centers have formalized their high standards through validation from the Plasma Protein Therapeutics Association's International Quality Plasma Program, recognition expected to include all 20 locations that will be opened by the end of 2024*
- *The certification from the plasma industry's top authority on quality and safety considers all key processes governing donor health and the quality of donor center operations to ensure the highest levels of excellence for the plasma used to make patient treatments*
- *It is a milestone in the public-private alliance between Grifols and the Egyptian government, which is advancing firmly in building the first integrated plasma-supply platform in the region*
- *The pioneering initiative is part of Grifols' global self-sufficiency program to meet the rising demand for plasma therapies*

**Barcelona, Spain, July 31, 2023** - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, has announced that its first donation centers in Egypt have been certified by the plasma industry's recognized authority on international quality and safety criteria, the only ones outside North America and Europe to receive this distinction.

Validation from the Plasma Protein Therapeutics Association's (PPTA) International Quality Plasma Program (IQPP), which confirms best industry practices through third-party audits, formalizes the high standards already followed by Grifols Egypt.

IQPP's certification now covers Grifols Egypt's first donation centers and is expected to eventually include all 20 locations that will be opened by the end of 2024. The recognition considers all key processes governing donor health and the quality of donor center operations to ensure the highest levels of excellence for the plasma used to make patient treatments.

Having its first donor centers certified is another defining moment for Grifols Egypt, which is moving steadily toward its goal of completing the world's only fully integrated plasma-supply platform, a showcase for plasma self-sufficiency in which plasma from Egyptians is manufactured into medicines in Egypt, used to treat Egyptian patients and strengthen the country's healthcare system.

# GRIFOLS

Soon hospitals in Egypt will receive delivery of the very first Grifols Egypt medicines, large quantities of albumin, used in major surgery and to treat trauma and burns. This begins a continuous stream of other lifesaving therapeutics that will also include immunoglobulins (Ig) for immunodeficiencies and blood-clotting factors to manage bleeding disorders. For the time being the treatments are being manufactured at Grifols' plant in Parets del Vallès (Barcelona) until the Grifols Egypt production facilities going up in the New Administrative Capital's medical city, along with testing and warehouse operations, are completed and operational.

"Grifols is proud of its IQPP certification in Egypt, another big step in establishing a game-changing integrated plasma collection and manufacturing infrastructure that will benefit patients in the country and entire region," said Raimon Grifols, Grifols Chief Corporate Officer.

"Recognition that our donor centers follow the highest and most demanding international operating norms is in line with Egypt's commitment to becoming a plasma and healthcare leader in the Middle East and Africa," said Dr. Magdy Amin, CEO Grifols Egypt.

Added Anita Brikman, PPTA President and CEO: "The PPTA notes that this is the first time that IQPP standards have been implemented in Africa, demonstrating the global importance of the industry's voluntary commitment to standards that go beyond regulatory requirements. PPTA is proud to welcome Grifols Egypt plasma donation centers to the IQPP family."

As demand for plasma medicines continues to grow, countries and regions are looking to ensure sustainable supplies. Through its Global Plasma Self-sufficiency Program, Grifols is spearheading innovative public-private alliances to help achieve strategic autonomy in essential plasma therapies. In addition to its partnership with the Egyptian government, Grifols has a long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in Ig medicines through an all-Canadian collection and manufacturing infrastructure.

---

## About Grifols Egypt for Plasma Derivatives

Grifols Egypt for Plasma Derivatives is a joint-venture company between Egypt's National Service Projects Organization and Grifols. The strategic partnership's combined expertise, technology and resources seeks to strengthen Egypt's healthcare system through achieving self-sufficiency in plasma-derived medicines while reinforcing Grifols' international expansion in the Middle East and Africa.

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to

# GRIFOLS

enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

## **Media contacts:**

### **Grifols**

#### **Media Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

### **Egypt**

#### **Egypt's National Service Projects Organization**

Email: [nspo@nspo.com.eg](mailto:nspo@nspo.com.eg)

Tel: +2021816946

## **Investors:**

### **Grifols Investors Relations Department**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Tel. +34 93 571 02 21

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group,

are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.